Factor IXa (FIXa) is known to have a binding site for heparin that has not been mapped by a mutagenesis study. By homology modeling based on structural data, we identified eight basic residues in the catalytic domain of FIXa that can potentially bind to heparin. 
Factor IXa (FIXa) 1 is a vitamin K-dependent coagulation serine protease, which upon binding to factor VIIIa on membrane surfaces in the presence of Ca 2ϩ forms the intrinsic Xase complex and rapidly activates factor X to factor Xa (FXa) during the blood coagulation process (1) (2) (3) . FIXa plays a key role in hemostasis, and its deficiency is associated with the life-threatening disease hemophilia B (4). The zymogen FIX circulates in plasma as a single-chain glycoprotein with 415 amino acids (4) . It can be converted to a functionally active form by either one of two physiological activators, the factor VIIa-tissue factor complex or factor XIa (1, 2, 5) . In addition, FIX can also be activated by a specific enzyme from Russell viper venom (RVV-X) (5) . Proteolytic cleavage by all three activators at two sites on the activation peptide (Arg 145 -Ala and Arg 180 -Val) removes a short peptide, thereby converting the zymogen to an active enzyme consisting of a light and a heavy chain held together by a single disulfide bond. Similar to other vitamin K-dependent coagulation proteases, the N-terminal light chain of FIXa contains the non-catalytic ␥-carboxyglutamic (Gla) domain and two epidermal growth factor (EGF)-like domains (6) . The catalytic domain of FIXa, with a trypsin-like primary specificity pocket, is located on the C-terminal heavy chain of the molecule (7) . The Gla and EGF1 domains of FIXa are involved in the Ca 2ϩ -dependent interaction with factor VIIIa on membrane surfaces (6, 8, 9) . Recent mutagenesis data have indicated that the protease domain of FIXa also interacts with factor VIIIa (9) . The role of the EGF2 domain in the function of FIXa is not well understood. However, a recent mutagenesis study demonstrated that the EGF2 domain is required for the structural integrity and localization of FIXa to membrane surfaces (10) .
The proteolytic activity of FIXa is primarily regulated by antithrombin (AT). Similar to its reaction with other coagulation proteases, AT by itself is a poor inhibitor of FIXa unless it binds to heparin-like glycosaminoglycans (11) . Heparin accelerates the rate of inactivation of coagulation proteases, including thrombin, FXa, and FIXa by 3 to 4 orders of magnitude (12) . It is well established that full-length heparin accelerates the AT inactivation of thrombin by a template mechanism (13) . In this mechanism of inactivation, the polysaccharide binds both to the protease and the serpin to enhance the rate of encounter complex formation (template mechanism). In inactivation of FIXa and FXa, however, the cofactor effect of a full-length heparin at physiologic levels of Ca 2ϩ is mediated by a 200 -300-fold enhancement by the heparin-induced conformational activation of the serpin and an additional several hundred-fold enhancement by a template mechanism (13) (14) (15) (16) .
Basic residues of the heparin binding exosites of both thrombin (17) (18) (19) and FXa (20) have been mapped by mutagenesis studies. These residues are shown to be clustered in similar three-dimensional locations in the catalytic domains of both coagulation proteases (21, 22) . This site in thrombin, which is referred to as "anion binding exosite 2" contains 11 basic residues. The structural data indicate that eight of the basic residues of this region are also conserved at the same or similar three-dimensional locations in FIXa (7) . To determine the contribution of each one of these residues to binding of FIXa to heparin, we generated eight separate mutants in which these residues were substituted with Ala. The mutants in the chymotrypsin numbering system (21), K98A, K126A, R165A, R170A, K173A, K230A, R233A, and K239A, which correspond to FIX numbering (mature peptide) (4) K265A, K293A, R333A, R338A, K341A, K390A, R393A, and K409A, were expressed in human 293 cells and purified to homogeneity. Following activation by RVV-X, the properties of the mutant enzymes were characterized with respect to their ability to cleave chromogenic substrates, directly bind heparin, and react with AT in both the absence and presence of full-length heparin or the high affinity pentasaccharide fragment of heparin. Both kinetic and direct binding data indicated that five basic residues, Lys 126 , Arg 165 , Arg 170 , Lys 230 , and Arg 233 , are critical for binding to heparin. Structural data suggest that all five residues are spatially aligned adjacent to each other (7), thus forming a basic exosite capable of interaction with heparin.
EXPERIMENTAL PROCEDURES
Mutagenesis and Expression of Recombinant Proteins-The wild type, K98A, K126A, R165A, R170A, K173A, K230A, R233A, and K239A mutants of FIX in Gla-domainless forms (GD-FIX) were constructed by PCR mutagenesis methods as described previously (23) . All FIX derivatives were expressed in the RSV-PL4 universal expression/purification vector system as described (23) . This vector contains the sequence of the transferrin signal peptide for secretion, the sequence of a 12-residue epitope for the Ca 2ϩ -dependent monoclonal antibody HPC4 for purification, and a neomycin gene for G418 selection in mammalian cells (23) . Following transfer of vectors into mammalian cells, G418-resistant clones were selected and examined for FIX expression by a sandwich enzyme-linked immunosorbent assay using the HPC4 monoclonal and a goat polyclonal antibody against human FIX purchased from Hematologic Technologies Inc. (Essex Junction, VT). A high expressing clone for each derivative was identified and expanded; 20 liters of cell culture supernatant were collected, concentrated, and purified by immunoaffinity chromatography using the HPC4 monoclonal antibody linked to Affi-gel 10 (Bio-Rad) as described (23) .
Human plasma AT, FIXa, and factor X activating enzyme from RVV-X were purchased from Hematologic Technologies Inc. Unfractionated heparin (heparin sodium injection, USP, 10,000 units/ml) from beef lung and the active AT-binding pentasaccharide fragment of heparin (fondaparinux sodium) were purchased from Quintiles Clinical Supplies (Mt. Laurel, NJ). Heparin-Sepharose was purchased from Amersham Biosciences, the chromogenic substrate CH 3 SO 2 -D-Leu-GlyArg-pNA (CBS 31.39) was purchased from Diagnostica Stago (Asnieres, France), and Polybrene was purchased from Sigma.
Binding to Heparin-Sepharose-Factor IX derivatives (ϳ250 g) in 0.02 M Tris-HCl (pH 7.5), 0.1 M NaCl (TBS buffer) containing 5 mM Ca 2ϩ were converted to their activated forms with 25 g of RVV-X for 3 h at 37°C as described previously (24) . The activation mixtures were applied on a 1-ml heparin-Sepharose column pre-equilibrated with the same buffer. The column was washed with 2 ml of the same buffer followed by elution with a step gradient of 0.1-0.5 M NaCl using increments of 10 mM salt. At each step, 1 ml of buffer was used to elute proteins. Twenty-five microliters from each fraction was transferred to a 96-well plate, and the amidolytic activities of the GD-FIXa derivatives toward the cleavage of the chromogenic substrate CBS 31.39 (1 mM final) were monitored at 405 nm at room temperature in a V max kinetic microplate reader (Molecular Devices, Menlo Park, CA). The active fractions were pooled, dialyzed in 0.1 M NaCl, 0.02 M Tris-HCl (pH 7.5), 0.02% NaN 3 , 5 mM CaCl 2 , and their active site concentrations were determined by titration with a known concentration of AT in the presence of pentasaccharide as described (25) .
Cleavage of Chromogenic Substrates-The steady-state kinetics of hydrolysis of CBS 31.39 (0.04 -5 mM) by FIXa derivatives (5-10 nM) were studied in TBS containing 0.1 mg/ml bovine serum albumin, 33% ethylene glycol, and 5 mM Ca 2ϩ . The rate of hydrolysis was measured at 405 nm at room temperature as described above. The apparent K m and k cat values for substrate hydrolysis were calculated from the MichaelisMenten equation, and the catalytic efficiencies were expressed as the ratios of k cat /K m .
Reaction with Antithrombin-The rate of inactivation of FIXa derivatives by AT in both the absence and presence of heparin and the pentasaccharide fragment of heparin was measured under pseudo firstorder rate conditions by a discontinuous assay as described previously (20) . In the absence of a cofactor, each FIXa derivative (20 nM) was incubated with AT (0.5-1.0 M) in TBS containing 0.1 mg/ml bovine serum albumin, 0.1% polyethylene glycol 8000, and 5 mM CaCl 2 for 45-90 min. All reactions were carried out in 50-l volumes in 96-well polystyrene assay plates at room temperature. In the presence of pentasaccharide, the reaction conditions were the same except that FIXa derivatives were incubated with AT (200 nM) in complex with a saturating concentration of pentasaccharide (1 M) for 1-5 min. In the presence of full-length heparin, each FIXa derivative (20 nM) was incubated with 200 nM AT in the presence of catalytic levels of heparin (0.6 -50 nM) for 10 s to 6 min in the same TBS buffer system. The reactions were stopped by addition of 50 l of CBS 31.39 (final concentration of 1.0 mM) in TBS containing 1 mg/ml Polybrene. The remaining enzyme activity was measured with a V max kinetics microplate reader at 405 nm as described above. The observed pseudo first-order rate constants (k obs ) were determined by fitting the time-dependent change of the protease activity to a first-order rate equation, and second-order rate constants (k 2 ) were obtained from the slopes of linear plots of k obs versus the concentrations of AT-heparin complexes as described (16) . The AT-heparin complex concentrations were calculated from the dissociation constant for the AT-heparin interaction and total concentrations of AT and heparin using the quadratic equation (26) . Noting the experimental conditions described above (200 nM AT) and a low K D for the interaction of heparin with AT (10 -20 nM), the calculated concentrations of the AT-heparin complexes were in close proximity to the concentrations of free heparin.
Data Analysis-The ENZFITTER (R.J. Leatherbarrow, Elsevier, Biosoft) computer program was used to fit data to appropriate equations. All values are the average of at least 3 independent measurements Ϯ S.E.
RESULTS

Expression and Purification of Recombinant Proteins-Wild
type and the Ala substitution mutants of FIX in Gla-domainless forms were expressed in 293 cells as described under "Experimental Procedures." Wild type and mutant molecules were separated from the cell culture supernatants by single step immunoaffinity chromatography using the HPC4 monoclonal antibody as described previously (23) . SDS-PAGE analysis of the purified proteins under non-reducing conditions indicated that the isolated proteins are relatively pure and that they all migrate with similar and expected molecular masses of ϳ60 kDa, suggesting that 293 cells properly processed the recombinant proteins (Fig. 1) .
The rationale for generating the mutants in Gla-domainless forms was to eliminate the possible interference of the anionic Gla domain with heparin binding to FIXa as previously demonstrated for other vitamin K-dependent coagulation proteases, FXa and activated protein C (27, 28) . Moreover, the Gla-domainless forms (EGF1, EGF2, and catalytic domains) of all vitamin K-dependent plasma proteins express well in mammalian cells by our universal expression/purification vector system and are then conveniently purified to homogeneity in a single step by the Ca 2ϩ -dependent monoclonal antibody, HPC4 (23) . This antibody recognizes a 12-residue epitope that is fused to the N-terminal end of the EGF1 domain in the expressed proteins. This modification has not adversely affected the catalytic properties of these enzymes in solution (23, 24, 29) . As shown below, this appears to be also true for FIXa because both plasma-derived FIXa and recombinant GD-FIXa exhibited essentially identical kinetic properties with respect to amidolytic activity toward the chromogenic substrate CBS 31.39 and reactivity with AT in both the absence and presence of polysaccharides. Binding to Heparin-Sepharose-All GD-FIX derivatives were activated with RVV-X, and their affinity for heparin was evaluated by a NaCl gradient elution of the enzymes from the heparin-Sepharose column as described (28) . The NaCl gradient elution profiles of all GD-FIXa derivatives are shown in Fig.  2 . The K98A, K173A, and K239A mutants interacted with the heparin column with normal affinities. This was evidenced by the observation that, similar to wild type GD-FIXa, peak activities for all three mutant enzymes were eluted at a similar NaCl concentration of 0.4 M. However, all other mutants required lower concentrations of salt to be eluted from heparinSepharose (Fig. 2) . The concentration of NaCl required to elute the peak activity of the other five mutants ranged from K126A (0.26 M) and R165A (0.22 M) to R170A (0.30 M), K230A (0.23 M), and R233A (0.21 M). As shown below, the degree of loss of the affinity of mutants for the heparin column correlated well with the extent of impairments in the template effect of a full-length heparin-catalyzed AT inhibition of these mutants.
Active peak fractions of GD-FIXa derivatives (Fig. 2) were pooled, concentrated, and dialyzed in TBS containing 0.1 M NaCl and 5 mM CaCl 2 . Purification of activated proteins on the heparin-Sepharose column resulted in separation of high molecular weight contaminants observed with certain GD-FIX derivatives shown in Fig. 1 , and thus all of the following experiments were carried out with essentially pure enzymes (data not shown). The active site concentrations of GD-FIXa derivatives were determined by stoichiometric titration with known concentrations of AT in the presence of pentasaccharide. The assay was also calibrated with known concentrations of plasma-derived FIXa.
Amidolytic Activity-Kinetic parameters for the hydrolysis of the chromogenic substrate CBS 31.39 by FIXa derivatives are presented in Table I . FIXa cleaved this chromogenic substrate with a high efficiency in the presence of 33% ethylene glycol. Relative to wild type, similar k cat of substrate hydrolysis was observed with all GD-FIXa derivatives. The K m value for the K98A mutant was improved 2-3-fold. All other derivatives exhibited K m values of 2.1-3.7 mM, suggesting that the mutagenesis of these basic residues may have no significant adverse effect on the catalytic pocket of FIXa derivatives. This is a reasonable assumption because all mutants are solvent-exposed in the crystal structure of FIXa (7) and similar results have been observed for the analogous substitution mutants of thrombin and FXa in previous studies (17, 20) .
Reaction with Antithrombin-The reactivities of FIXa derivatives with AT were evaluated in both the absence and presence of a full-length heparin and the pentasaccharide fragment of heparin. Similar to improvement in the amidolytic activity, the reactivity of K98A with AT was improved 2-3-fold in both the absence and presence of cofactors (Table II) . Relative to wild type, there were insignificant changes in the reactivity of all other GD-FIXa derivatives with AT in the absence and presence of pentasaccharide (Table II) . At physiological levels of Ca 2ϩ , both plasma-derived FIXa and GD-FIXa exhibited similar second-order association rate constants (k 2 ) in reaction with AT in the presence of heparin (Fig. 3A) . However, the cofactor effect of heparin in accelerating the AT inhibition of mutant proteases was impaired to varying degrees. Relative to GD-FIXa, the heparin-catalyzed k 2 values were improved for K98A and minimally affected for the K173A and K239A mutants (Table II) . On the other hand, a significant decrease in the k 2 values was observed for all other mutants, ranging from a minimum of an ϳ4-fold decrease for R170A to a maximum of ϳ27-fold decrease for R233A (Fig. 3B and Table II) .
Analysis of the kinetic data of Table II suggests that the catalytic effect of heparin in the AT inhibition of FIXa derivatives is mediated through both the conformational activation of the serpin by the pentasaccharide fragment of heparin and a template mechanism mediated through the long chain heparin bridging the two proteins in one complex. Assuming that the active conformer of AT, whether it is activated by heparin or the pentasaccharide fragment of heparin, makes a similar contribution to the rate-accelerating effect of the protease inhibition (13) , it may be possible to estimate the extent of the template effect of a full-length heparin in the reaction. This can be done by dividing the k 2 values in the presence of heparin to the same values in the presence of the pentasaccharide. These values are calculated and presented in the last column of Table  II . Analysis of these data suggests that heparin accelerates the AT inhibition of wild type FIXa 200 -300-fold through a conformational activation of AT and 200 -300-fold through the template mechanism. This is essentially the same result we previously reported for the heparin-catalyzed AT inhibition of Gladomainless FXa or FXa in the presence of physiological concentrations of Ca 2ϩ (16) . Thus, AT regulates the proteolytic activities of both FIXa and FXa by a similar mechanism.
DISCUSSION
The direct binding and kinetic data both indicated that five basic residues Lys 126 , Arg 165 , Arg 170 , Lys 230 , and Arg 233 constitute a basic exosite in the catalytic domain of FIXa that can bind to heparin. The location and relative orientation of these residues in the crystal structure of the catalytic domain of FIXa are shown in Fig. 4 (7) . The order of importance of these were applied on a 1-ml heparin-Sepharose column followed by elution with a step gradient of 0.1-0.5 M NaCl using increments of 10 mM salt as described under "Experimental Procedures." The symbols are: wild type (E), K98A (q), K126A (f), R165A (Ⅺ), R170A (‚), K173A (OE), K230A (ƒ), R233A (), and K239A (छ). The kinetic constants were calculated from the cleavage rate of increasing concentrations of CBS 31.39 (0.04 -5 mM) by each FIXa derivative (10 nM) in TBS buffer containing 5 mM Ca 2ϩ , 0.1 mg/ml bovine serum albumin, and 33% ethylene glycol as described under "Experimental Procedures." residues for binding heparin is: Arg 233 Ͼ Arg 165 Ͼ Lys 230 Ͼ Lys 126 Ͼ Arg 170 . Although these residues are located apart from each other in the linear sequence of FIXa they are, nonetheless, spatially aligned adjacent to each other on the threedimensional structure of the molecule. Arg 233 appears to make the greatest contribution to the binding of FIXa to heparin. This residue, together with Lys 230 , is located on the C-terminal ␣-helix of FIXa. Previous studies have indicated that basic residues of the same ␣-helix in both FXa (Lys 236 and Arg 240 ) and thrombin (Arg 233 , Lys 236 , and Lys 240 ) are also the most critical residues for binding to heparin (17, 19, 20) . In these latter two proteases, two basic residues of the 99-loop (Arg   93 and Arg 97 in thrombin and Arg 93 and Lys 96 in FXa) are also part of the heparin binding exosites (20, 30) . Indeed, mutation of the single residue Arg 93 nearly eliminated all cofactor effect of a full-length heparin in accelerating the AT inhibition of thrombin (30) . In the case of FIXa, however, the 99-loop has a single basic residue (Lys 98 ) that is not involved in an interaction with heparin. Instead, the basic charge of this residue appears to contribute to the low reactivity of FIXa with AT and its poor catalytic efficiency toward the chromogenic substrate CBS 31.39. This is derived from the observation that the kinetic properties of the K98A mutant are improved at least 2-3-fold in all reactions studied. In agreement with these results, a previous study showed that exchanging several residues of the 99-loop (encompassing Lys 98 ) between FIXa and FXa switches the specificity of these enzymes (31) . This was judged by an improvement in the catalytic activity of FIXa but impairment in the activity of the homologous FXa mutant (31) . Results of the current study suggest that Lys 98 may have been a key contributor to specificity changes of the 99-loop swap mutants of FIXa and FXa in that previous study.
Arg 165 and Arg 170 , the other two residues of FIXa critical for binding to heparin, are located on the 162-170-helix. The homologous residues in FXa (Arg 165 and Lys 169 ) also bind to heparin (20) . Previous mutagenesis studies have indicated that Arg 165 plays a key role in the cofactor-dependent interactions of FIXa (9) and FXa (20) The inactivation rates in the absence of the cofactors (k 2,uncat ) were determined from the residual activities of the FIXa derivative (20 nM) after incubation at room temperature with AT (0.5-1.0 M) for 45-90 min in TBS buffer, containing 0.1 mg/ml bovine serum albumin and 0.1% polyethylene glycol 8000, as described under "Experimental procedures." The k 2,penta values were determined by the same procedures except that 20 nM enzyme was incubated with 200 nM AT for 1-5 min in the presence of 1 M pentasaccharide. The k 2,H values were determined by the same procedures except that the FIXa derivatives were incubated with AT (200 nM) in the presence of heparin (0.6 -50 nM) for 10 sec to 6 min and k 2 values were determined from the slopes of linear plots of k obs versus the concentrations of AT-heparin complexes as shown in Fig. 3 . mutation of this residue in FIXa dramatically impaired the factor VIIIa-dependent activation of factor X in the intrinsic pathway of the coagulation cascade (9) . Similarly, the analogous mutant of FXa (and also Lys 169 ) exhibited a severe catalytic defect during prothrombin activation in the presence of factor Va in the prothrombinase complex (20) . It appears, therefore, basic residues of the 162-loop in both FIXa and FXa can bind to heparin as well as their specific cofactors and/or substrates in the activation complexes. However, relative to interaction of FXa with heparin, we predict that residues of the 162-loop of FIXa would make a greater contribution to the binding energy of the interaction because both mutants of FIXa bound more weakly to heparin-Sepharose than the analogous mutants of FXa. This was evidenced by their elution from the heparin column at lower ionic strengths. Thus, in contrast to NaCl concentrations of 0.22 M (Arg 165 ) and 0.30 M (Arg 170 ), which were required to elute the FIXa mutants in the current study (Fig. 2) , a higher salt concentration of 0.35 M was required in a previous study to elute the mutants of FXa from the same type of heparin column (20) . It should be noted that wild type Gla-domainless forms of both proteases were eluted at ϳ0.4 M NaCl, suggesting that they have similar affinities for heparin (20) .
It is known that in the purified system therapeutic doses of heparin can directly inhibit factor X activation by the intrinsic Xase complex independent of AT but have no effect on the activation of prothrombin by the prothrombinase complex (32) . The mechanism by which heparin differentially affects properties of these two homologous procoagulant activation complexes is not known. The results presented above suggest that the binding of heparin to the 162-loop of FIXa may interfere with the assembly of the intrinsic Xase complex. However, because heparin has a lower affinity for the 162-loop of FXa, it may not efficiently compete with factor Va/prothrombin for binding to this site of the protease and thus is unable to directly inhibit the prothrombinase complex. In support of this hypothesis, a recent study demonstrated that a hypersulfated heparin, which has an improved affinity for interaction with these proteases, is effective in directly inhibiting both the intrinsic and prothrombinase complexes independent of membrane surfaces (33) . These results can best be described by a model in which hypersulfated heparin disrupts the assembly of activation complexes by competing with specific cofactors and/or substrates of FIXa and FXa for binding to the 162-loop of these procoagulant proteases.
